Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Synaptogenix stock

Learn how to easily invest in Synaptogenix stock.

Synaptogenix, Inc. Common Stock
NASDAQ: SNPX - USD
BIOTECHNOLOGY
$8.17
+$0.57 (+7.50%)

Synaptogenix, Inc. Common Stock is a biotechnology business based in the US. Synaptogenix shares (SNPX) are listed on the NASDAQ and all prices are listed in US Dollars. Synaptogenix employs 4 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy shares in Synaptogenix

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – SNPX – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Synaptogenix stock price (NASDAQ: SNPX)

Use our graph to track the performance of SNPX stocks over time.

Synaptogenix shares at a glance

Information last updated 2021-07-28.
52-week range$0.65 - $14.40
50-day moving average $9.72
200-day moving average $8.82
Wall St. target priceN/A
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) N/A

Buy Synaptogenix shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
Stocks, ETFs, Cryptocurrency
N/A
0%
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Webull
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $3.00 and $300 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Public
Stocks, ETFs
N/A
$0 per month
Download and sign up with Public.com; approved accounts receive a free stock slice worth up to $70, selected from 9 popular stocks.
Open an account
Commission-free trading in stocks and ETFs with a social networking twist.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
0%
N/A
INVESTMENT AND INSURANCE PRODUCTS ARE: NOT A DEPOSIT • NOT FDIC INSURED • NO BANK GUARANTEE • MAY LOSE VALUE
Robinhood
Stocks, Options, ETFs
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Moomoo
Stocks, Options, ETFs
$0
$0 per year
N/A
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Synaptogenix stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Synaptogenix financials

Gross profit TTM $0
Return on assets TTM -56.58%
Return on equity TTM -112.63%
Profit margin 0%
Book value $4.39
Market capitalisation $55.9 million

TTM: trailing 12 months

Shorting Synaptogenix shares

There are currently 549,729 Synaptogenix shares held short by investors – that's known as Synaptogenix's "short interest". This figure is 456.6% up from 98,763 last month.

There are a few different ways that this level of interest in shorting Synaptogenix shares can be evaluated.

Synaptogenix's "short interest ratio" (SIR)

Synaptogenix's "short interest ratio" (SIR) is the quantity of Synaptogenix shares currently shorted divided by the average quantity of Synaptogenix shares traded daily (recently around 2.1 million). Synaptogenix's SIR currently stands at 0.26. In other words for every 100,000 Synaptogenix shares traded daily on the market, roughly 260 shares are currently held short.

However Synaptogenix's short interest can also be evaluated against the total number of Synaptogenix shares, or, against the total number of tradable Synaptogenix shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Synaptogenix's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Synaptogenix shares in existence, roughly 40 shares are currently held short) or 0.0878% of the tradable shares (for every 100,000 tradable Synaptogenix shares, roughly 88 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Synaptogenix.

Find out more about how you can short Synaptogenix stock.

Synaptogenix share dividends

We're not expecting Synaptogenix to pay a dividend over the next 12 months.

Synaptogenix overview

Synaptogenix, Inc. operates as a biopharmaceutical company. It focuses on developing a product platform based upon a drug candidate called bryostatin for the treatment of Alzheimer's disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and niemann-pick type C disease. It has licensing agreements with Stanford University; Icahn School of Medicine; and The Board of Trustees of the Leland Stanford Junior University. The company was incorporated in 2012 and is based in New York, New York. .

Stocks similar to Synaptogenix

Frequently asked questions

What percentage of Synaptogenix is owned by insiders or institutions?
Currently 31.443% of Synaptogenix shares are held by insiders and 12.186% by institutions.
How many people work for Synaptogenix?
Latest data suggests 4 work at Synaptogenix.
When does the fiscal year end for Synaptogenix?
Synaptogenix's fiscal year ends in December.
Where is Synaptogenix based?
Synaptogenix's address is: 1185 Avenue of the Americas, New York, NY, United States, 10036

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site